GGrantIndex
← Search

Program 2: Cancer Imaging Program (CIP)

$33,828P30FY2018CANIH

University Of Arizona, Tucson AZ

Investigators

Linked publications, trials & patents

Paper 39631050Paper 39622842Paper 39612086Paper 39361227Paper 39312766Paper 39151774Paper 39100646Paper 39075233Paper 38875929Paper 38858600Paper 38826434Paper 38804255Paper 38769192Paper 38759377Paper 38729260Paper 38719743Paper 38715255Paper 38687603Paper 38658768Paper 38639990Paper 38613866Paper 38612480Paper 38474232Paper 38464045Paper 38453918Paper 38386696Paper 38386396Paper 38328594Paper 38313301Paper 38309054Paper 38291312Paper 38215755Paper 38203706Paper 38199366Paper 38164625Paper 38164604Paper 38097734Paper 38097593Paper 38096366Trial NCT07214506Trial NCT06009926Trial NCT05699603Trial NCT05237960Trial NCT05121051Trial NCT04530552Trial NCT03708055Trial NCT03602066Trial NCT03601507Trial NCT03578432Trial NCT03422536Trial NCT03402230Trial NCT03376971Trial NCT03365895Trial NCT03196180Trial NCT02581137Trial NCT02568566Trial NCT02348203Trial NCT02326805Trial NCT02123849Trial NCT01686165Trial NCT01433913Trial NCT01394211Trial NCT01385280Trial NCT01370889Trial NCT01288261Trial NCT01172028Trial NCT01097304Trial NCT01077453Trial NCT00980395Trial NCT00978718Trial NCT00900432Trial NCT00900341Trial NCT00898703Trial NCT00896935Trial NCT00892268Trial NCT00841204Trial NCT00752739Trial NCT00732498Trial NCT00721877Trial NCT00702299Trial NCT00701857Trial NCT00699907Trial NCT00619060Trial NCT00608634Trial NCT00601640Trial NCT00410618Trial NCT00373022Trial NCT00363805Trial NCT00303823Trial NCT00245024Trial NCT00091325Trial NCT00078897Trial NCT00003307Trial NCT00003082Patent 9486545Patent 9435812Patent 9415110Patent 9262824Patent 5650489Patent 5510240

Abstract

Project Summary / Abstract: Cancer Imaging Program (CIP) The scientific goal of the Cancer Imaging Program (CIP) is to develop and apply imaging technologies and imaging methods for cancer prevention and intervention studies. Members of the CIP are working at the forefront of the field and have been eminently successful in utilizing the theoretical underpinnings of imaging science to advance new imaging technologies for a wide array of critical cancer applications. Program activities are organized under three major themes: Theme 1) Advancement of major biomedical imaging technologies for cancer; Theme 2) Molecular imaging and the development of advanced contrast agents, including analysis of their mechanisms; and Theme 3) Advancement of theoretical image science related to cancer. The CIP provides a dynamic cancer-focused environment that fosters inter-programmatic collaborations with a robust translational pipeline that facilitates entry of research applications into investigator-initiated clinical trials (IITs). CIP has two Specific Aims: Aim 1) To promote advances in imaging science and technology and their application in the context of cancer biology, early cancer detection, development and monitoring of cancer therapies, and cancer prevention studies; Aim 2) To promote translation of the science into clinical trials and development and testing of new technologies in the clinic through investigator-initiated clinical trials (IITs) and coordinated validation at other clinical sites. CIP leadership, in cooperation with the UACC and University of Arizona (UA) leadership, is instrumental in securing sources for pilot funding for prototype testing/development and in providing access to unique laboratory and clinical methodologies to aid researchers who are involved in the discovery and development of new diagnostic methods and new anticancer therapies. The CIP builds on the UA's excellence in imaging science. The CIP has 31 Members, from 10 different departments, with complementary, specialized skills drawn from multiple colleges and departments across the UA. Joint appointments in multiple departments and membership in Graduate Interdisciplinary Programs provide the dynamic networks of interaction required for highly innovative research. The effective integration of the diverse Membership into cancer imaging research, combined with funded mentoring and training programs, have resulted in the sustained, broad-based development of novel approaches to cancer diagnosis/therapy and significant high-impact contributions. CIP Members have contributed to 249 cancer-relevant manuscripts, of which 33% were intra-programmatic and 31% were inter-programmatic. As of September 1, 2015, the CIP Program secured more than $7.5M in total annual grant dollars, with $3M of that from the NCI and $4M in other peer-reviewed funding. Major funding held by Program Members includes a Center Grant (P41EB002035) that supports UA's ?Center for Gamma Ray Imaging? and a Training grant (T32EB000809) entitled ?Biomedical Imaging and Spectroscopy.?

View original record on NIH RePORTER →